p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy
Jack D Chan, Paul A Beavis, Phillip K Darcy
CANCER CELL | CELL PRESS | Published : 2020
In this issue of Cancer Cell, Gurusamy et al. use a CRISPR-Cas9 screening approach to demonstrate that deletion of p38 increases multiple phenotypic qualities of effective anti-tumor T cells. Preconditioning T cells with a p38 inhibitor enhances anti-tumor efficacy of adoptive immunotherapy.
Related Projects (2)
Awarded by National Breast Cancer Foundation Fellowship
Awarded by NHMRC Senior Research Fellowship
The authors wish to acknowledge funding support from the National Health and Medical Research Council of Australia, the National Breast Cancer Foundation, Cancer Council of Victoria, and the CLEARbridge Foundation. J.D.C. is supported by a Robert Kirby Award (2020). P.A.B. is supported by a National Breast Cancer Foundation Fellowship (ID#ECF-17-005). P.K.D. is supported by an NHMRC Senior Research Fellowship (APP1136680).